Belenos Biosciences
↗New York, NY, USA
Belenos Biosciences is a clinical-stage biotechnology company focused on developing next-generation, long-acting bispecific antibody therapeutics to transform the treatment of chronic inflammatory diseases. The company aims to make clinical remission the standard of care for conditions such as asthma, chronic obstructive pulmonary disease (COPD), and atopic dermatitis.
Founded in 2024 with backing from OrbiMed, Belenos utilizes a 'pipeline-in-a-product' approach, engineering its bispecific antibodies with half-life extension technology to enable more durable disease control and improved patient adherence. The company has secured exclusive rights to assets developed by Keymed Biosciences for markets outside of Greater China.
CLASSIFICATION
Company Type:Biotech
Therapeutic Areas:
Industry:Biotechnology
Sub-Industry:Immunology / Bispecific Antibodies
SIZE & FINANCIALS
Employees:1-50
Founded:2024
Ownership:private
Status:operating
FUNDING
Stage:Series A
Total Raised:$48M
Investors:OrbiMed
PIPELINE
Stage:Phase 1/2
Lead Drug Stage:Phase 2 (in China)
Modalities:Bispecific antibodies
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Keymed Biosciences (Licensing agreement for CM512/BEL512 and CM536/BEL536)
COMPETITION
Position:Emerging
Competitors:Regeneron, Sanofi, AstraZeneca, Eli Lilly
LEADERSHIP
Key Executives:
Donnie McGrath - CEO & Co-Founder
Megan Dow - COO & Co-Founder
LINKS
Website:belenosbio.com
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Belenos Biosciences and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Belenos Biosciences. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.